Fierce Pharma
NOVEMBER 6, 2024
Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its GLP-1 stalwarts Ozempic and Wegovy is more of a mixed bag. | Among Novo’s semaglutide-based drugs, diabetes blockbuster Ozempic fell short of analysts' expectations during the third quarter while weight-loss med Wegovy came above a consensus estimate.
MedCity News
NOVEMBER 6, 2024
By focusing on integrating care teams, expanding community programs, and addressing SDoH through policy reform, we can create a healthcare system that serves all patients — especially those most in need. The post Patients Across the Country Deserve Better Access to Healthcare appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 6, 2024
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a past COVID-19 vaccine supply deal. The Maryland biotech has agreed to pay $123.8 million to end a COVID vaccine supply pact with the U.K.
Pharmaceutical Technology
NOVEMBER 6, 2024
The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor optimism improved following the interest rate cuts by the US Federal Reserve in September 2024.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Pharma
NOVEMBER 6, 2024
Drugs for unmet needs and those from experienced companies had the best chance for successful launches in 2023: report kdunleavy Wed, 11/06/2024 - 09:23
MedCity News
NOVEMBER 6, 2024
Acadia Pharmaceuticals did not disclose the buyer of the priority review voucher. The biotech received the voucher last year alongside the regulatory decision that made its drug Daybue the first FDA-approved treatment for the rare disease Rett syndrome. The post Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
NOVEMBER 6, 2024
As a leader who has committed much of his career to improving healthcare — an industry that holds millions of people’s lives in its hands — I took from this terrifying incident a new guiding principle. Healthcare needs to pursue a zero-failure rate. The post What My Daughter’s Harrowing Alaska Airlines Flight Taught Me About Healthcare appeared first on MedCity News.
pharmaphorum
NOVEMBER 6, 2024
Novo Nordisk's sales of blockbuster obesity drug Wegovy grew by a massive 79% in the third quarter, in a relief to investors after disappointing results three months ago.
MedCity News
NOVEMBER 6, 2024
Mental health experts are hopeful about the de-stigmatization of behavioral health, the promise of AI and other areas, they shared at a recent conference. The post 4 Areas Within Mental Health Care that Give Executives Hope appeared first on MedCity News.
pharmaphorum
NOVEMBER 6, 2024
New results with Alligator's CD40 agonist mitazalimab show it nearly doubled survival in pancreatic cancer, ahead of phase 3 trial next year.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
European Pharmaceutical Review
NOVEMBER 6, 2024
Dupixent (dupilumab) has been approved by the European Medicines Agency (EMA) as the first treatment for young children with eosinophilic esophagitis in the EU. This authorisation is based on Phase III data which found that 68 percent of children aged one to 11 years given Dupixent (dupilumab) achieved histological disease remission at 16 weeks. This result was maintained for up to one year.
pharmaphorum
NOVEMBER 6, 2024
Two players in medical extended reality (XR) – XRHealth and NeuroReality – have come together in a quest to build the biggest company in the sector.Boston, US-based XRHealth is leading the deal, acquiring NeuroReality of the Netherlands for an undisclosed sum, combining their products and expertise in the use of XR and virtual reality software for healthcare applications.
Pharmaceutical Commerce
NOVEMBER 6, 2024
In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, forecasts the future of the pharma cold chain regarding technological advancements and changes in market dynamics.
PharmaTimes
NOVEMBER 6, 2024
New therapy targets specific genetic alterations, promises extended survival
Pharma Marketing Network
NOVEMBER 6, 2024
The world of digital marketing in pharma is evolving rapidly. With technological advances and changing consumer expectations, the industry must adapt or risk falling behind. Pharma marketing executives face the unique challenge of staying compliant while engaging audiences in meaningful ways. So, how can digital marketing truly revolutionize the pharma space?
Clarify Health
NOVEMBER 6, 2024
Now more than ever, health plans are under increasing pressure to deliver high-quality, cost-effective care across their provider networks. Balancing quality and profitability requires more than just contracting with providers; it demands a strategic approach to network management that prioritizes both performance and efficiency. One of the most powerful tools available for achieving this balance is healthcare data analytics.
PharmExec
NOVEMBER 6, 2024
At the Financial Times’ Global Pharma and Biotech Summit 2024, a breakout panel discussed how dealmaking remains vital for biopharma companies facing pipeline and revenue pressures.
PharmaVoice
NOVEMBER 6, 2024
After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 diabetes therapy.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmExec
NOVEMBER 6, 2024
At the Financial Times’ Global Pharma and Biotech Summit 2024, a panel discussed initiatives aimed at bringing cell and gene therapies to low- and middle-income countries.
Pharmaceutical Technology
NOVEMBER 6, 2024
Tevogen Bio’s AI effort Tevogen.AI has partnered with Microsoft to advance the development of an HPV specific CTL treatment.
PharmExec
NOVEMBER 6, 2024
Industry experts comment on the increasing popularity of compounded medications, particularly GLP-1s, due to drug shortages and the desire for personalized treatments.
PharmaTech
NOVEMBER 6, 2024
Data governance, data integrity, and data quality are all widely used terms, but what do they actually mean and how are they connected?
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
PharmExec
NOVEMBER 6, 2024
Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explored the potential implications of the phase-out of cookies for the broader advertising industry.
Pharmaceutical Technology
NOVEMBER 6, 2024
The FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal trial”.
PharmExec
NOVEMBER 6, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
PharmaTimes
NOVEMBER 6, 2024
Phase 1 and 2 studies show promising results for anito-cel therapy
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Technology
NOVEMBER 6, 2024
The UWWTD will require manufacturers to fund micropollutant removal, but Zentiva says the financial squeeze could mean shortages.
Pharmaceutical Commerce
NOVEMBER 6, 2024
Digital transformation initiatives are often complex endeavors that can significantly impact the way organizations operate.
Pharmaceutical Technology
NOVEMBER 6, 2024
Demis Hassabis, joint winner of the Nobel Prize in Chemistry 2024, shared insights on AI at the FT Pharma and Biotech Summit.
Pharmacy Times
NOVEMBER 6, 2024
Jeff Boyer, PharmD, BCPS, discusses his role in opioid stewardship at the Southern Arizona VA Healthcare System, highlighting his work in pain management coordination, interdisciplinary collaboration, patient and provider education, and data-driven strategies to support safe opioid use and address the opioid crisis.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
176 
Let's personalize your content